CCR5 Antagonist Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced Subjects

Washington-based CytoDyn Inc. today announced that a research paper entitled “Leronlimab (PRO 140) activity against 4-class drug-resistant...

CCR5 Antagonist Conducting Phase 3 Study for Critically Ill COVID-19 Patients

Washington-based CytoDyn Inc. today announced that it had received a positive response from the U.S. Food and Drug Administration ("FDA") to...